BDX
Becton Dickinson insider trading
Health Care · Heavy selling
Close · Oct 5, 2026
$180.67
+22.7% over 12 months
Share price and insider trades
BDX closeInsider buyInsider sale
Bought, 12 months$0
Sold, 12 months$2.8M
Insiders buying0
Insiders selling5
Valuation, profit and volume
P/E (trailing)n/aSector median 24.5
Market value—
Profit margin—Revenue growth —
Volume vs. 50-day0.9×Last 5 sessions
Insiders' paper profit—On all tracked purchases —
Summary
Over the past 12 months, 0 Becton Dickinson insiders reported open-market purchases totaling $0, while 5 insiders reported sales totaling $2.8M. 19 of 22 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
Insider transactions
Open-market purchases and sales. 56 grants, option exercises and tax withholdings are not shown.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Sep 29SEC | Michael FeldEvp, Chief Revenue Officer | Sell Plan | 76 | $183.70 | $14K | -1.6% | — |
| Aug 27SEC | Michael FeldEvp, Chief Revenue Officer | Sell Plan | 165 | $188.49 | $31K | -4.1% | — |
| Aug 14SEC | Thomas E Polen Jr.CEO, President | Sell Plan | 4,152 | $185.00 | $768K | -2.3% | — |
| Aug 12SEC | Roland GoettePresident | Sell | 2,438 | $180.84 | $441K | -0.1% | — |
| Jul 28SEC | Michael FeldEvp, Chief Revenue Officer | Sell Plan | 75 | $157.13 | $12K | +15.0% | — |
| Jun 26SEC | Michael FeldEvp, Chief Revenue Officer | Sell Plan | 75 | $152.80 | $11K | +18.2% | — |
| Jun 25SEC | Michael David GarrisonEvp & Pres Med.Essntl&Biopharm | Sell Plan | 1,100 | $145.66 | $160K | +24.0% | — |
| Jun 11SEC | Michael David GarrisonEvp & Pres Med.Essntl&Biopharm | Sell Plan | 1,100 | $151.48 | $167K | +19.3% | — |
| Jun 3SEC | Thomas E Polen Jr.CEO, President | Sell Plan | 2,764 | $146.35 | $405K | +23.5% | — |
| May 27SEC | Michael FeldEvp, Chief Revenue Officer | Sell Plan | 75 | $147.35 | $11K | +22.6% | — |
| Apr 28SEC | Michael FeldEvp, Chief Revenue Officer | Sell Plan | 74 | $151.94 | $11K | +18.9% | — |
| Mar 27SEC | Michael FeldEvp, Chief Revenue Officer | Sell Plan | 75 | $156.83 | $12K | +15.2% | — |
| Feb 27SEC | Michael FeldEvp, Chief Revenue Officer | Sell Plan | 75 | $181.84 | $14K | -0.6% | — |
| Feb 18SEC | Bertram L ScottDirector | Sell | 953 | $182.61 | $174K | -1.1% | — |
| Jan 28SEC | Michael FeldEvp, Cro & Pres. Life Sciences | Sell Plan | 75 | $202.73 | $15K | -10.9% | — |
| Jan 16SEC | Michael David GarrisonEvp & Pres Med.Essntl&Biopharm | Sell Plan | 1,010 | $206.54 | $209K | -12.5% | — |
| Jan 16SEC | Michael David GarrisonEvp & Pres Med.Essntl&Biopharm | Sell Plan | 600 | $209.00 | $125K | -13.6% | — |
| Dec 29SEC | Michael FeldEvp, Cro & Pres. Life Sciences | Sell Plan | 74 | $196.08 | $15K | -7.9% | — |
| Dec 17SEC | Michael David GarrisonEvp & Pres Med.Essntl&Biopharm | Sell Plan | 629 | $196.03 | $123K | -7.8% | — |
| Dec 2SEC | Michael FeldEvp, Cro & Pres. Life Sciences | Sell Plan | 75 | $193.36 | $15K | -6.6% | — |
| Nov 7SEC | Bertram L ScottDirector | Sell | 217 | $176.58 | $38K | +2.3% | — |
| Oct 28SEC | Michael FeldPresident | Sell Plan | 57 | $186.01 | $11K | -2.9% | — |
Insiders at Becton Dickinson
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Thomas E Polen Jr.CEO, President | — | $1.2M | Aug 14, 2026 | — |
| Michael David GarrisonEvp & Pres Med.Essntl&Biopharm | — | $784K | Jun 25, 2026 | — |
| Roland GoettePresident | — | $441K | Aug 12, 2026 | — |
| Bertram L ScottDirector | — | $212K | Feb 18, 2026 | — |
| Michael FeldEvp, Chief Revenue Officer | — | $171K | Sep 29, 2026 | — |
| Vitor RoqueCFO | — | — | Sep 3, 2026 | — |
| Bilal MuhsinPresident | — | — | Jul 6, 2026 | — |
| Peter MenziusoPresident | — | — | Jun 2, 2026 | — |
| Shana Carol NealEvp And Chief People Officer | — | — | Apr 6, 2026 | — |
| Lanesha MinnixGeneral Counsel | — | — | Mar 17, 2026 | — |
| Pamela L. SpiknerSvp Controller & Cao | — | — | Mar 4, 2026 | — |
| Jacqueline WrightDirector | — | — | Jan 29, 2026 | — |
| Joanne WaldstreicherDirector | — | — | Jan 29, 2026 | — |
| Timothy M RingDirector | — | — | Jan 29, 2026 | — |
| Christopher Ian Montague JonesDirector | — | — | Jan 29, 2026 | — |
| Robert Luther HuffinesDirector | — | — | Jan 29, 2026 | — |
| William M BrownDirector | — | — | Jan 29, 2026 | — |
| Gregory HayesDirector | — | — | Jan 29, 2026 | — |
| Carrie L ByingtonDirector | — | — | Jan 29, 2026 | — |
| R Andrew EckertDirector | — | — | Jan 29, 2026 | — |
| Jeffrey William HendersonDirector | — | — | Jan 29, 2026 | — |
| David ShanEvp And Chief Isc Officer | — | — | Jan 6, 2026 | — |
| Richard ByrdPresident | — | — | Dec 1, 2025 | — |
| Christopher DeloreficeCFO | — | — | Dec 1, 2025 | — |
| Pavan Kumar MocherlaPresident | — | — | Dec 1, 2025 | — |
Insider activity at other Health Care companies
Same sector, ranked by insider buying in the last 90 days.
Common questions about BDX insiders
Are Becton Dickinson insiders buying BDX stock?
In the past 12 months, 0 insiders reported open-market purchases of BDX worth $0.
Are Becton Dickinson insiders selling BDX stock?
5 insiders reported sales worth $2.8M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.